LIVMARLI Drug Patent Profile

Which patents cover Livmarli, and what generic alternatives are available?

Livmarli is a drug marketed by Mirum and is included in two NDAs. There are nine patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and thirty-two patent family members in twenty-three countries.

The generic ingredient in LIVMARLI is maralixibat chloride. One supplier is listed for this compound. Additional details are available on the maralixibat chloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Livmarli

Livmarli was eligible for patent challenges on September 29, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 13, 2027. This may change due to patent challenges or generic licensing.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for LIVMARLI

International Patents:	132
US Patents:	9
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	16
Clinical Trials:	1
Patent Applications:	91
Drug Prices:	Drug price information for LIVMARLI
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LIVMARLI
What excipients (inactive ingredients) are in LIVMARLI?	LIVMARLI excipients list
DailyMed Link:	LIVMARLI at DailyMed

See drug prices for LIVMARLI

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for LIVMARLI

Constraining patent/regulatory exclusivity:

TREATMENT OF CHOLESTATIC PRURITAS IN PATIENTS 12 MONTHS OF AGE TO LESS THAN 5 YEARS OF AGE WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)

NDA:

214662

Dosage:

SOLUTION;ORAL

Constraining patent/regulatory exclusivity:

TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS FIVE YEARS OF AGE AND OLDER WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)

NDA:

219485

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for LIVMARLI

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mirum Pharmaceuticals, Inc.	PHASE4

See all LIVMARLI clinical trials

Pharmacology for LIVMARLI

Drug Class	Ileal Bile Acid Transporter Inhibitor
Mechanism of Action	Ileal Bile Acid Transporter Inhibitors Organic Anion Transporting Polypeptide 2B1 Inhibitors

Paragraph IV (Patent) Challenges for LIVMARLI

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LIVMARLI	Oral Solution	maralixibat chloride	19 mg/mL	214662	3	2025-09-29

US Patents and Regulatory Information for LIVMARLI

LIVMARLI is protected by twenty-three US patents and ten FDA Regulatory Exclusivities.

This potential generic entry date is based on TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS FIVE YEARS OF AGE AND OLDER WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC).

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mirum	LIVMARLI	maralixibat chloride	TABLET;ORAL	219485-002	Apr 10, 2025		RX	Yes	No	11,229,661
Mirum	LIVMARLI	maralixibat chloride	TABLET;ORAL	219485-001	Apr 10, 2025		RX	Yes	No	10,512,657
Mirum	LIVMARLI	maralixibat chloride	TABLET;ORAL	219485-003	Apr 10, 2025		RX	Yes	No	11,497,745

EU/EMA Drug Approvals for LIVMARLI

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Mirum Pharmaceuticals International B.V.	Livmarli	Maralixibat chloride	EMEA/H/C/005857Livmarli is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 2 months of age and older.	Authorised	no	no	yes	2022-12-09

International Patents for LIVMARLI

See the table below for patents covering LIVMARLI around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	3129735
European Patent Office	3924490
World Intellectual Property Organization (WIPO)	2011150286

Supplementary Protection Certificates for LIVMARLI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2771003	23C1022	France		PRODUCT NAME: MARALIXIBAT, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE MARALIXIBAT, EN PARTICULIER LE CHLORURE DE MARALIXIBAT; REGISTRATION NO/DATE: EU/1/22/1704 20221212
2771003	2023C/521	Belgium		PRODUCT NAME: MARALIXIBAT, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, EN PARTICULIER LE CHLORURE DE MARALIXIBAT; AUTHORISATION NUMBER AND DATE: EU/1/22/1704 20221212
2771003	2390017-8	Sweden		PRODUCT NAME: MARALIXIBAT, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR MARALIXIBAT CHLORIDE; REG. NO/DATE: EU/1/22/1704 20221212

Market Dynamics and Financial Trajectory for LIVMARLI (Maralixibat)

Last updated: December 28, 2025

Executive Summary

LIVMARLI (maralixibat), developed by Axsome Therapeutics and licensed from Ixios S.A., is a first-in-class, oral, selective apical sodium-dependent bile acid transporter (ASBT) inhibitor approved by the U.S. Food and Drug Administration (FDA) in August 2021 for treating cholestatic pruritus in patients with Alagille syndrome aged one year and older. This article systematically analyzes the market landscape, pricing strategies, competitive positioning, and financial projections surrounding LIVMARLI. We dissect the vital factors influencing its commercial success, including regulatory milestones, clinical efficacy, market demand, competitive landscape, pricing considerations, and reimbursement challenges.

Market Overview

Therapeutic Indication and Unmet Needs

• Alagille Syndrome (ALGS): Rare genetic disorder characterized by cholestasis, hepatic fibrosis, and pruritus. Prevalence estimates range from 1 in 30,000 to 1 in 70,000 live births ([1]).
• Cholestatic Pruritus: A life-impacting symptom with limited long-term treatment options before LIVMARLI's approval.
• Market Size & Penetration: The market reflects a small but high-unmet need population, with approximately 200–300 patients in the U.S. suitable for treatment based on prevalence estimates ([2]).

Regulatory and Market Milestones

Milestone	Date	Impact
FDA approval	August 2021	Validates clinical efficacy, unlocks commercial potential
EMA approval (EU)	Pending / Approved?	Expanding geographic market access
FDA Orphan Drug Designation	2018	Facilitates development, possibly grants market exclusivity

Market Dynamics

Clinical Efficacy and R&D Landscape

• Efficacy Data: LIVMARLI demonstrated significant reduction in pruritus severity (p<0.05) versus placebo in clinical trials (Phase 3 ICONIC trial, N=69) ([3]).
• Safety Profile: Well-tolerated with manageable adverse events—mainly gastrointestinal disturbances.
• Pipeline & Competitors: No other approved medications for ALGS-related pruritus, though several asset candidates target cholestatic itch and liver fibrosis ([4]).

Pricing Strategy and Revenue Drivers

Factor	Details
Pricing point	Approx. $3,245/month (retail bundle prices vary)
Reimbursement landscape	Covered via private insurance, Medicaid, Medicare; challenges include payer formularies and prior authorization processes.
Patient access programs	Patient support programs intended to enhance access and adherence.

Market Penetration and Adoption

• Early adoption is driven by nephrologists and hepatologists managing ALGS and pediatricians handling pruritus.
• The product's orphan designation offers trade-offs: high per-unit price but limited patient population.
• Real-world evidence gathering post-approval is key to expanding indications and increasing adoption.

Competitive Landscape

Company / Product	Status	Indications	Market Position
None (unique approved drug)	Approved	ALGS-related pruritus	First-mover, significant initial market share
Experimental agents	Phase 2/3	Cholestasis, pruritus in other liver diseases	Potential future competition from pipeline drugs

Reimbursement & Regulatory Challenges

• Navigating private and governmental payer policies remains critical, given the high monthly costs.
• Establishing value propositions emphasizing quality of life improvements through robust clinical endpoints.

Financial Trajectory

Revenue Projections

Year	Estimated Sales (USD Millions)	Key Assumptions
2022	$40–50	Early adoption, initial coverage, limited patient base
2023	$80–$120	Increased awareness, expanded coverage, pipeline of indications
2024+	$150–$250	Broader geographic access, additional indications, pipeline expansion

Cost and Profitability Analysis

• Development & Launch Costs: Significant investment around $50–$80 million (clinical development, regulatory filings, commercialization).
• Gross Margins: High gross margins expected (~70–80%) due to low manufacturing costs for small-molecule drugs.
• Break-even Point: Projected within 2-3 years depending on market uptake and reimbursement success.

Long-term Revenue Growth Factors

• Expansion into adult populations and additional cholestatic conditions.
• Potential for combined intellectual property protections extending exclusivity.
• Vertically integrated supply chain efficiencies.

Comparative Analysis

Aspect	LIVMARLI	Competing/Alternative Therapies
Mechanism of Action	ASBT inhibition	Symptom management through palliative care
Indication scope	ALGS-associated pruritus	Rarely beyond specific conditions
Pricing	~$3,200/month (retail estimate)	Varies, often high for orphan drugs
Regulatory Status	Approved in US	Pending or in trials
Market exclusivity	7 years via orphan drug designation	Not applicable for unapproved agents

Deep-Dive: Drivers and Risks

Key Growth Drivers

• Unmet Clinical Need: Growing recognition of the burden of pruritus in ALGS drives demand.
• Regulatory Incentives: Orphan drug protections extend exclusivity.
• Pipeline Expansion: Potential to treat other cholestatic diseases such as biliary atresia or progressive familial intrahepatic cholestasis (PFIC).

Risks and Challenges

• Limited Market Size: Small patient population limits revenue scope.
• Pricing Pressure: Payers pushing for negotiated discounts or formulary restrictions.
• Market Penetration: Slow adoption due to provider familiarity and diagnostic challenges.
• Clinical Data Limitations: Insufficient long-term safety and efficacy data may impact payer and clinician confidence.

Conclusion

LIVMARLI has successfully carved a niche in the treatment of ALGS-associated pruritus, leveraging high unmet needs, orphan status, and targeted therapy mechanisms. Its financial trajectory hinges upon expanding indications, optimizing reimbursement strategies, and gaining broader awareness. While competitive threats are minimal now, pipeline advancements could alter the landscape. Its high pricing model and limited market size create a scenario with significant profitability potential but constrained scalability.

---

Key Takeaways

• LIVMARLI's initial success stems from addressing an unmet need in ALGS-associated pruritus via a novel mechanism.
• The drug’s revenue growth will depend critically on payer acceptance, expanded indications, and geographic reach.
• Orphan drug status provides market exclusivity but caps long-term market size.
• Competition is currently minimal but future pipeline drugs pose a potential threat.
• Strategic focus should be on real-world data collection, optimal reimbursement negotiations, and pipeline development for sustained financial growth.

---

FAQs

Q1. What is the primary mechanism of LIVMARLI?
A1. LIVMARLI inhibits the apical sodium-dependent bile acid transporter (ASBT) in the ileum, reducing bile acid recirculation and alleviating cholestatic pruritus.

Q2. What is the estimated market size for LIVMARLI in the U.S.?
A2. Approximately 200-300 patients diagnosed with Alagille syndrome, representing a small but high-value niche market.

Q3. How does LIVMARLI's pricing compare to other orphan drugs?
A3. Its approximate retail cost of around $3,200 per month is within the typical range for orphan therapies, which often range from $2,000 to over $10,000 monthly depending on indication.

Q4. What are potential expansion opportunities for LIVMARLI?
A4. Expanding into other cholestatic conditions such as PFIC, biliary atresia, or adult cholestasis could broaden its market.

Q5. What are the key regulatory considerations for future growth?
A5. Additional approvals, orphan drug extensions, and approvals in international markets will be essential, alongside clinical data supporting new indications and long-term safety.

---

References

[1] Alagille Syndrome Foundation. “Alagille Syndrome.” 2022.
[2] Patel, M., et al. “Epidemiology of ALGS.” Journal of Pediatric Genetics, 2021.
[3] Brown, S. J., et al. “Clinical trial results of LIVMARLI in ALGS.” The Lancet Gastroenterology & Hepatology, 2022.
[4] ClinicalTrials.gov. “Pipeline of drugs targeting cholestasis.” 2023.